Since these mechanisms are likely to be instrumental to the anti-cancer efficacy of EGFR-, Raf- and MEK-directed inhibitors, improvement in the targeted delivery of these drugs to malignant cells represents a valid strategy in the effort to limit their off target toxicity [68]. This evidence concerns the gene EGFR and cancer.